RE:No PartnerAny new partner would likely be a non-exclusive non-inventory distributor unless TSO3 is acquired, but this is all only speculation, as you know. Real negotiations with a new partner couldn't be seriously undertaken until last week's cancellation of the Getinge deal and I would think TSO3 management before inking any new deals will want a full assessment of the 20 new sales from Getinge not yet installed as well as a clear view of the pipeline of 100 quotes and other expressions of interest. My impression is that Getinge was seeing considerable traction following duo-scope FDA approval that truly again differentiated the VP4 from the competition and I think RR was only able to do such a deal in TSO3's favour back in January as there were repeated FDA approval delays and the people at Getinge were not convinced this approval would ever happen. Hence, in light of their pessimism and internal dysfunction of right hand not knowing what the left was doing, they put the VP4 on the back burner for the first 5 months of this year and signed away their VP4 inventory at a considerable loss which they probably regret and are now upset about. And, RR needed to undo the deal and take charge as he couldnt sit by and let Getinge continue to flounder with his disruptive product. In past weeks, RR saw an opportunity to go on his own as I believe he wants to build TSO3 into a full service sterilization company, not just a low temperature solution supplier, and be a rival to Steris, ASP/Fortive, and Cantel, at the very least. My guess is Getinge was such a dysfunctional disaster (poor reputation in the field in US, only serving half of NA hospitals, revolving door in management, cash flow and profit issues, spinning off a division,...) that RR was loathe to sign back onto an exclusive partnership without minimums and Getinge had failed to meet these anyway but didn't want to be non-exclusive... And, Getinge probably didn't think RR would walk. TSO3 however has been able to draw on Getinges presence to at least get the initial launch done, early market traction, and, with orders finally taking off, we don't need Getinge as much as before. With 230 units bought back at only 33k each that can be put into the market aggressively to solidify an installed base and steady ongoing consumables income, TSO3 should do very well and is extremely undervalued. But, I do believe and agree TSO3 would benefit from having a distribution deal with someone, once they have a handle on their pipeline going forward as they should in the next few weeks. Getinge is not the only game in town! My favorite in the space is actually Belimed, a Swiss owned company with a strong world wide presence, especially strong covering NA and the EU. I have no evidence that there have been any discussions between TSO3 and Belimed, but I have been looking more into BeliMed and their parent company Metall Zug AG as they purchased in 2017 70% of the best quality slit lamp microscope and eye diagnostics company in the world that I happen to use in ophthalmology, Haag Streit. This shows management obviously likes to go with the best at Belimed. Infection Control division is a main division of the company, with Business area of this division being split off this fall. They have 1200 world wide employees, stagnating income, plans to restructure their Infection control area underway, and, very significantly, they also bought the tiny Portugese LTS company Sterifast in early 2017 as a microscopic (pun intended) entry into the LTS space. Sterifast is a non-entity that had no sales of significance, consisted of the CEO plus only 2 employees, and was based in Portugal with one insignificant patent re: computer guided injection of H2O2, I believe. But, this acquisition does show BeliMeds interest in entering and being a player in the growing LTS industry. They are better run than Getinge and would be a great fit with TSO3, IMHO as a non-exclusive distributor or more. They have no LTS footprint or product on the market yet they have a booth as big as Getinge's and Steris's at Mexico City world sterilization conference meeting this October. I have speculated, and been mistaken thus far, that an entity such as Fortive/ASP, Steris, Cantel, 3M, Getinge, or Belimed would attempt a hostile takeover following the recent FDA news given the obvious opportunity provided by these ludicrously low share price levels of TOS, (TSO3's patents were increased world wide in the past quarter and total 150+ and are worth at least $3+ to the competition), and I remain surprised we have not yet seen an offer on the table. Though management, I believe, wants to keep TSO3 independent and grow it into the major player in sterilization it can be, any offer must be presented to shareholders, as you know. It's also very good to see RR now at least has some skin in the game with his 500,000 new shares: he is finally becoming properly aligned with shareholders!! (As has been noted, if he were planning to sell any of his new shares, this would typically have been prearranged as a block and executed coincident with him exercising his soon to expire options.) GTLA